Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas


Por: Garcia-Carbonero R, Teresa F, Mercader-Cidoncha E, Mitjavila-Casanovas M, Robledo M, Tena I, Alvarez-Escola C, Aristegui M, Bella-Cueto M, Ferrer-Albiach C, Hanzu F

Publicada: 1 oct 2021 Ahead of Print: 1 may 2021
Resumen:
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla and the sympathetic/parasympathetic neural ganglia, respectively. The heterogeneity in its etiology makes PPGL diagnosis and treatment very complex. The aim of this article was to provide practical clinical guidelines for the diagnosis and treatment of PPGLs from a multidisciplinary perspective, with the involvement of the Spanish Societies of Endocrinology and Nutrition (SEEN), Medical Oncology (SEOM), Medical Radiology (SERAM), Nuclear Medicine and Molecular Imaging (SEMNIM), Otorhinolaryngology (SEORL), Pathology (SEAP), Radiation Oncology (SEOR), Surgery (AEC) and the Spanish National Cancer Research Center (CNIO). We will review the following topics: epidemiology; anatomy, pathology and molecular pathways; clinical presentation; hereditary predisposition syndromes and genetic counseling and testing; diagnostic procedures, including biochemical testing and imaging studies; treatment including catecholamine blockade, surgery, radiotherapy and radiometabolic therapy, systemic therapy, local ablative therapy and supportive care. Finally, we will provide follow-up recommendations.

Filiaciones:
Garcia-Carbonero R:
 UCM, Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Dept Med Oncol,CNIO,CIBERONC, Avda Cordoba Km 5-4, Madrid 28041, Spain

Teresa F:
 Hosp Clin San Carlos, Dept Radiol, Madrid, Spain

Mercader-Cidoncha E:
 Hosp Gen Univ Gregorio Maranon, Gen & Digest Surg Dept, Endocrine & Metab Surg Unit, Madrid, Spain

Mitjavila-Casanovas M:
 Hosp Univ Puerta Hierro, Dept Nucl Med, Majadahonda, Spain

 Grp Trabajo Endocrino SEMNIM, Madrid, Spain

Robledo M:
 Spanish Natl Canc Res Ctr, Hereditary Endocrine Canc Grp, Madrid, Spain

 Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain

Tena I:
 Med Sci Innovat Res MedSIR CORP, Dept Sci, Ridgewood, NJ USA

 Hosp Prov, Dept Med Oncol, Castellon de La Plana, Spain

Alvarez-Escola C:
 Hosp Univ La Paz, Endocrinol & Nutr Dept, Neuroendocrinol Unit, Madrid, Spain

Aristegui M:
 Hosp Gen Univ Gregorio Maranon, ENT Dept, Madrid, Spain

Bella-Cueto M:
 Univ Autonoma Barcelona, Dept Pathol, Inst Invest & Innovacio Parc Tauli I3PT, Hosp Univ Parc Tauli, Sabadell, Spain

Ferrer-Albiach C:
 Hosp Prov Castellon, Dept Radiat Oncol, Castellon de La Plana, Spain

Hanzu F:
 Univ Barcelona, Hosp Clin Barcelona, Endocrinol & Nutr Dept, IDIBAPS, Barcelona, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 23 Número: 10
Páginas: 1995-2019
WOS Id: 000647997300001
ID de PubMed: 33959901
imagen Green Published, hybrid

MÉTRICAS